Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • 11 hours ago

Zoetis (ZTS) Ascends While Market Falls: Some Facts to Note

In the most recent trading session, Zoetis (ZTS) closed at $78.8, indicating a +1.29% shift from the previous trading day.

Zacks Investment Research • 3 hours ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks Investment Research • Oct 28, 2026

Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note

In the latest trading session, Zoetis (ZTS) closed at $81.03, marking a -1.18% move from the previous day.

Zacks Investment Research • Oct 23, 2026

ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?

Zoetis offers diversification and stability, while ImmuCell boasts stronger sales growth and expansion potential.

Zacks Investment Research • Oct 21, 2026

Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections.

Business Wire • Oct 20, 2026

Zoetis Appoints Iris Knobloch to its Board of Directors

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. With decades of experience across global media and consumer businesses, Ms. Knobloch brings a distinct combination of international leadership, proven public company board experience across financial services, hospitality and media, and deep consumer and digital expertise to the Zoetis Board. She currently serves on the boards of.

Business Wire • Oct 13, 2026

Top 50 High-Quality Dividend Growth Stocks For October 2026

I track an investable universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and future return potential. Applied Materials, D.R. Horton, and Home Depot saw notable ranking improvements due to upgraded EPS growth estimates and/or favorable valuation shifts. 44 out of 50 stocks currently offer a forward return estimate of at least 10%, with 32 appearing potentially undervalued based on free cash flow mean reversion.

Seeking Alpha • Oct 11, 2026

10 Dividend Growth Stocks: October 2026

In this monthly series, I rank a selection of dividend growth stocks and present the top 10 stocks for consideration. This month's screen targets dividend growth stocks with Dividend Safety scores ≥8.0, forward yields ≥2.5%, and prices at or below fair value. An equally weighted portfolio of the top 10 stocks yields 2.8% but would have underperformed SPY over the past 5 years.

Seeking Alpha • Oct 12, 2026

Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know

In the most recent trading session, Zoetis (ZTS) closed at $74.81, indicating a +2.37% shift from the previous trading day.

Zacks Investment Research • Oct 9, 2026